Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00084565
Recruitment Status : Withdrawn (Study was never activated at Fox Chase Cancer Center.)
First Posted : June 11, 2004
Last Update Posted : July 10, 2013
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : November 2004
  Actual Study Completion Date : November 2004